Clinical Trials Logo

Filter by:
NCT ID: NCT03891030 Recruiting - Clinical trials for Maternal Health Service

Checklist Based Box System Interventions

CBBSI
Start date: November 22, 2018
Phase: N/A
Study type: Interventional

Maternal mortality is still high in Ethiopia. Antenatal care (ANC), use of skilled delivery attendants and postnatal care (PNC) services are key maternal health care services that can significantly reduce maternal mortality. However, interventions applied to the continued utilization of these key maternal heath services in a continuum of care approach (i.e. early initiation of ANC and continued utilization up to four plus vists, health facility delivery attended by skilled health care providers and attending three PNC visits) were not well applied and studied. Hence, the purpose of this study is to test the effectiveness of checklist based box system interventions on improving utilization of maternal health service (Antenatal care, skilled birth attendance and postnatal care) utilization.

NCT ID: NCT03890237 Recruiting - Adolescent Behavior Clinical Trials

GAGE Act With Her-Ethiopia Evaluation

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the impact of Act With Her Ethiopia (AWH-E), a gender transformative multi-level program that aims to improve the lives of young adolescent boys and girls.

NCT ID: NCT03889431 Completed - Infant Development Clinical Trials

Community Salt Testing and Relation of Iodine Intake to Visual Information Processing of Ethiopian Infants

Start date: January 2, 2013
Phase: N/A
Study type: Interventional

This study evaluated efficacy of iodized salt for mothers and their six-month-old infants' thyroid hormones and visual information processing. Half of the participants received 450 g iodized salt for the household each week, while the other half received 225 ug iodine daily as a potassium iodide capsule.

NCT ID: NCT03886519 Recruiting - Surgery Clinical Trials

Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial

PTT
Start date: April 13, 2019
Phase: N/A
Study type: Interventional

The objective of this study is to determine if there is a significant difference in post-operative trichiasis at 12 months comparing a new procedure, the Bevel/rotate/advance procedure (BRAP), to the Trabut procedure among repeat surgery patients.

NCT ID: NCT03854435 Not yet recruiting - Perinatal Asphyxia Clinical Trials

Determination of Heart Rate in Infants Needing Resuscitation at Birth

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Algorithms for neonatal resuscitation adapted to low resource settings include HR evaluation by auscultation or umbilical cord palpation at about one minute of life. Previous studies conducted in high resource settings showed that auscultation of the precordium is more accurate than umbilical palpation to assess HR of healthy infants at birth.The last versions of the American Heart Association and the European Resuscitation Council Guidelines on Neonatal resuscitation suggest that "during resuscitation of term and preterm newborns, the use of 3-lead ECG for the rapid and accurate measurement of the newborn's heart rate may be reasonable". However, this remains a weak recommendation with a very-low-quality evidence. In low resource countries, a stethoscope is rarely available and palpation of the umbilical pulse is the method used for detecting HR. Although this is preferable to other palpation sites (i.e. femo-ral and brachial artery), there is a high likelihood of underestimating HR with palpation of the umbilical pulse in healthy infants. The accuracy of assessing HR by auscultation and umbilical palpation in newborn infants requir-ing resuscitation remains unknown. To the investigator's knowledge, there are not previous studies that have compared the accuracy of HR estima-tion by auscultation vs. umbilical palpation in newborn infants needing resuscitation This study was designed to compare two different methods (auscultation and umbilical cord pal-pation) of HR estimation in newborn infants needing resuscitation, in order to determine which method is most suitable for use in clinical practice.

NCT ID: NCT03837431 Recruiting - Clinical trials for Cutaneous Leishmaniases

Cutaneous Leishmaniasis Diagnostic Study

Start date: February 13, 2019
Phase:
Study type: Observational

The performance of the CL Detect Rapid test will be tested in individuals with suspected cutaneous leishmaniasis in Ethiopia using both skin slit and dental broach samples against a combined reference of microscopy and PCR. Alternative sampling methods will also be evaluated.

NCT ID: NCT03813069 Suspended - Trachoma Clinical Trials

Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma

Start date: January 10, 2019
Phase: Phase 2
Study type: Interventional

Musca sorbens, a fly that feeds from ocular and nasal discharge on humans, is thought to be the vector of trachoma. We are developing methods of fly control that specifically target this species, in the hope of interrupting Ct transmission. To our knowledge, the use of commercially available insect repellents has never been tested for prevention of Musca sorbens fly-eye contact (i.e. nuisance and landing in the peri-ocular area). Given the likely necessity for prolonged and/or high frequency fly-eye contact for Ct transmission, the reduction of these contacts through the use of fly repellents presents an exciting opportunity for disease control. Here we propose a within-subject, non-masked, trial of the use of commercially available insect repellents against Musca sorbens, with two consecutive participant groups in the laboratory and in the field, and a primary endpoint of measuring the protective efficacy of each repellent product. Repellent products will be chosen from: DEET (N,N-diethyl-3-methylbenzamide), IR3535 (3-[N-butyl-N-acetyl]-aminopropionic acid ethyl ester), Picaridin (2-(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl ester); PMD (para-Menthane-3,8-diol) or permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate). Products tested will be either (1) topical repellents, or (2) in long-lasting, plastic formulations of repellents that can be worn on the body (wearable repellent technologies). The insect repellent synergist Vanillin (4-Hydroxy-3-methoxybenzaldehyde) may be added to the long-lasting plastic formulations, to improve the duration of protection.

NCT ID: NCT03775460 Not yet recruiting - Clinical trials for Erythema Nodosum Leprosum

Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum

MaPs
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Erythema Nodosum Leprosum (ENL) is a painful, debilitating complication of leprosy. Patients often require high doses of corticosteroids for prolonged periods. Thalidomide is expensive and not available in most countries. The use of corticosteroids for long periods is associated with adverse effects and mortality. It is a priority to identify alternative agents to treat ENL. Methotrexate (MTX) is a cheap, widely used medication which has been reported to be effective in ENL resistant to steroids and thalidomide.

NCT ID: NCT03761459 Enrolling by invitation - Surgery Clinical Trials

Current Surgical Practices and Surgical Site Infection at Ayder Comprehensive Specialized Hospital in Mekelle, Ethiopia

Start date: March 20, 2018
Phase:
Study type: Observational [Patient Registry]

This study evaluates the current surgical practices at Ayder Comprehensive Specialized Hospital in comparison to the World Health Organization's Surgical Unit Based Safety Programme guidelines and aims to determine how deviations from those guidelines are associated with varying rates of surgical site infection incidence in this population. The results of this study will help elucidate risk factors for surgical site infection and prioritize future interventions to decrease the rate of surgical site infection at Ayder Comprehensive Specialized Hospital, as well as other low and middle-income hospitals. The data collected regarding surgical site infection rates will also prove beneficial in measuring outcomes of any interventions that are developed as a result of this study.

NCT ID: NCT03754322 Recruiting - Malaria Clinical Trials

The Impact of Molecular Diagnosis of Malaria With LAMP in Pregnant Women

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Malaria is one of the major public health problems in sub-Saharan Africa. It contributes significantly to maternal and fetal morbidity and mortality in affected countries. The aim of this study is to evaluate the impact of enhanced case detection using molecular testing (LAMP) on maternal and infant morbidity and mortality in a prospective study design. A pilot prospective diagnostic efficacy study will be conducted from October 2018 until October 2019 in pregnant mothers at three sites in Ethiopia. Both symptomatic and asymptomatic first trimester mothers will be included in the study and individually randomized to either standard of care or one of two enhanced cased detection arms using LAMP for malaria. Mothers in the first trimester will be enrolled during a seven month period from October 2018 to October 2019 and then followed until delivery. Given the rate of pregnant mothers at the three sites, we anticipate 500 mothers in total enrolled in the study during the study period. In the first standard of care arm, venous blood sample will be collected from each study participant and the presence of Plasmodium infection will be diagnosed by microscopy in symptomatic patients. Pregnant women who test positive for malaria will be referred and treated for malaria with quinine or artemisin combination therapies (ACTs) as per national guidelines. In the second (test) arm, mothers will be tested by a commercially available CE-approved LAMP malaria test at each clinic visit in lieu of microscopy. In the third (test) arm, mothers whether symptomatic or asymptomatic will be tested by both microscopy and LAMP for malaria at each clinic visit and treated if positive by either test. Pregnant mothers who require treatment will be referred and treated with either quinine or artemisinin combination therapy (ACTs) as per national guidelines. The primary outcomes are (i) maternal anemia (ii) infant anemia at birth and (iii) fetal birth weight in each of the three arms.